Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Lung peptidases, including carboxypeptidase, modulate airway reactivity to intravenous bradykinin.

Chodimella V, Skidgel RA, Krowiak EJ, Murlas CG.

Am Rev Respir Dis. 1991 Oct;144(4):869-74.

PMID:
1928964
2.

Bradykinin-induced airway microvascular leakage is potentiated by captopril and phosphoramidon.

Lötvall JO, Tokuyama K, Barnes PJ, Chung KF.

Eur J Pharmacol. 1991 Aug 6;200(2-3):211-7.

PMID:
1782987
3.

Metabolism of bradykinin by peptidases in the lung.

Dragović T, Igić R, Erdös EG, Rabito SF.

Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1491-6.

PMID:
8389109
4.

Neutral endopeptidase and angiotensin converting enzyme inhibitors potentiate kinin-induced contraction of ferret trachea.

Dusser DJ, Nadel JA, Sekizawa K, Graf PD, Borson DB.

J Pharmacol Exp Ther. 1988 Feb;244(2):531-6.

PMID:
3279179
5.

Dexamethasone reduces tachykinin but not ACh airway hyperreactivity after O3.

Murlas CG, Lang Z, Chodimella V.

Lung. 1993;171(2):109-21.

PMID:
7678875
6.

Peptidase modulation of noncholinergic vagal bronchoconstriction and airway microvascular leakage.

Lötvall JO, Tokuyama K, Löfdahl CG, Ullman A, Barnes PJ, Chung KF.

J Appl Physiol (1985). 1991 Jun;70(6):2730-5. Erratum in: J Appl Physiol 1991 Sep;71(3):following Table of Contents. J Appl Physiol 1991 Dec;71(6):following Author Index.

PMID:
1885469
7.
8.

Pulmonary C-fiber activation before and after peptidase inhibition in rats.

Bergren DR, Ustinova EE, Schultz HD.

Respir Physiol. 1997 Feb;107(2):99-109.

PMID:
9108624
9.

Bradykinin is less potent in causing airway microvascular leakage in immature than in adult guinea-pigs. Role of neutral endopeptidase.

Yokoyama T, Tokuyama K, Morikawa A, Kuroume T.

Eur J Pharmacol. 1993 Jun 4;236(3):427-32.

PMID:
8359201
10.

Role of neutral endopeptidase in bronchial hyperresponsiveness to bradykinin induced by IL-1 beta.

Tsukagoshi H, Sun J, Kwon O, Barnes PJ, Chung KF.

J Appl Physiol (1985). 1995 Mar;78(3):921-7.

PMID:
7775337
11.

The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.

Sulpizio AC, Pullen MA, Edwards RM, Brooks DP.

J Pharmacol Exp Ther. 2004 Jun;309(3):1141-7. Epub 2004 Feb 9.

12.
13.

[T-kinin-induced increase in airway vascular permeability and its modulation by angiotensin-converting enzyme].

Takeda Y, Tamaoki J, Yamawaki I, Chiyotani A, Konno K.

Nihon Kyobu Shikkan Gakkai Zasshi. 1996 Jun;34(6):627-31. Japanese.

PMID:
8741526
14.

Endothelial angiotensin-converting enzyme and neutral endopeptidase in isolated human umbilical vein: an effective bradykinin inactivation pathway.

Nowak W, Errasti AE, Armesto AR, Santín Velazque NL, Rothlin RP.

Eur J Pharmacol. 2011 Sep 30;667(1-3):271-7. doi: 10.1016/j.ejphar.2011.05.045. Epub 2011 Jun 1.

PMID:
21651905
17.

Degradation of bradykinin by neutral endopeptidase (EC 3.4.24.11) in cultured human endothelial cells.

Graf K, Gräfe M, Bossaller C, Niehus J, Schulz KD, Auch-Schwelk W, Fleck E.

Eur J Clin Chem Clin Biochem. 1993 May;31(5):267-72.

PMID:
8395230
18.

Degradation of bradykinin in human urine by carboxypeptidase Y-like exopeptidase and neutral endopeptidase and their inhibition by ebelactone B and phosphoramidon.

Saito M, Majima M, Katori M, Sanjou Y, Suyama I, Shiokawa H, Koshiba K, Aoyagi T.

Int J Tissue React. 1995;17(5-6):181-90.

PMID:
8835628
19.
20.

Role of angiotensin converting enzyme in the vascular effects of an endopeptidase 24.15 inhibitor.

Telford SE, Smith AI, Lew RA, Perich RB, Madden AC, Evans RG.

Br J Pharmacol. 1995 Mar;114(6):1185-92.

Supplemental Content

Support Center